Though mostly off the front pages these days, the war against HIV goes on - and last week a new therapeutic recruit showed some of its colors, as Incyte Corp. unveiled data from a Phase IIb trial with the once-daily pill Reverset, yet another nucleoside analogue reverse transcriptase inhibitor (NRTI).
After sifting through would-be licensors, Depomed Inc. is entering a $50 million deal with Esprit Pharma Inc. to market and distribute Proquin XR, the extended-release form of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections. (BioWorld Today)
With the way apparently clearing for approval of its low-molecular-weight heparin, Momenta Pharmaceuticals Inc. raised about $130.4 million by selling about 4.8 million shares of stock at $27.02 each. (BioWorld Today)
Lucentis is on the march. Again.Last week, Genentech Inc. released the detailed data from the Phase III MARINA study of Lucentis (ranibizumab) in wet age-related macular degeneration, confirming interim data disclosed in May - but the news got even better.
About a week after reporting solid second-quarter sales for its anti-nausea drug Aloxi for chemotherapy patients, MGI Pharmaceuticals Inc. disclosed its plan to buy out Guilford Pharmaceuticals Inc. for $177.5 million in cash and stock - thus adding to its cancer portfolio and more. (BioWorld Today)
Affymax Inc. raised $60 million in a Series D financing to push along its Phase II candidate Hematide for anemia, which is expected to be studied in four separate trials by late fall. (BioWorld Today)
